Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

The TP53 tumor suppressor gene is frequently mutated in human cancers. An analysis of five data platforms in 10,225 patient samples from 32 cancers reported by The Cancer Genome Atlas (TCGA) enables comprehensive assessment of p53 pathway involvement in these cancers. More than 91% of TP53-mutant cancers exhibit second allele loss by mutation, chromosomal deletion, or copy-neutral loss of heterozygosity. TP53 mutations are associated with enhanced chromosomal instability, including increased amplification of oncogenes and deep deletion of tumor suppressor genes. Tumors with TP53 mutations differ from their non-mutated counterparts in RNA, miRNA, and protein expression patterns, with mutant TP53 tumors…

• BC
  Baylor College of Medicine
• RF
  Radiumhemmets Forskningsfonder
• NI
  National Institutes of Health

  Awards: CA210950, CA016672, UM1HG008898, U24 CA210949, W81XWH, P30 CA016672, U24 CA210950
• UO
  University of Texas MD Anderson Cancer Center
• NC
  National Cancer Institute

  Awards: P30 CA016672, CA016672, DoD/CDMRP W81XWH-16-1-0237, W81XWH-16-1-0237, U24 CA210950, U24 CA199461, CA210950, UM1HG008898, U24 CA210949
• CD
  Congressionally Directed Medical Research Programs

  Awards: CA016672, W81XWH-16-1-0237